Capital Research Global Investors Trims Holdings in DexCom, Inc.

The investment firm reduced its stake in the medical device company by over 56% in the third quarter.

Mar. 12, 2026 at 8:20am

Got story updates? Submit your updates here. ›

Capital Research Global Investors lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 56.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund now owns 2,367,676 shares of the medical device company's stock, down from 5,406,619 shares previously.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are important medical devices for people with diabetes. The reduction in Capital Research Global Investors' stake could signal a shift in investor sentiment around the company's future prospects.

The details

Capital Research Global Investors sold 3,038,943 shares of DexCom during the third quarter, reducing its total holdings to 2,367,676 shares worth $159,321,000. This was part of a broader trend, as other major institutional investors like Vanguard Group Inc. and Massachusetts Financial Services Co. MA also increased or decreased their DexCom positions during the quarter.

  • Capital Research Global Investors filed its 13F report for the third quarter of 2026.

The players

Capital Research Global Investors

A large investment management firm that is a subsidiary of the Capital Group Companies.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring systems for people with diabetes.

Vanguard Group Inc.

One of the world's largest investment management companies, known for its index funds and ETFs.

Massachusetts Financial Services Co. MA

A large asset management firm based in Boston that invests in a variety of sectors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The reduction in Capital Research Global Investors' DexCom stake suggests a potential shift in investor sentiment around the company, which could have implications for the broader CGM market and diabetes management technology. However, the overall institutional ownership of DexCom remains high, indicating continued confidence in the company's long-term prospects.